scanX
IPCA Laboratories
add_icon

IPCA Laboratories

1,935.20
+14.80
(0.77%)
Market Cap
49,096.84 Cr
PE Ratio
35.45
Volume
4,27,716.00
Day High - Low
1,958.60 - 1,911.60
52W High-Low
1,945.10 - 1,251.60
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
49,096.84 Cr
EPS
44.98
PE Ratio
35.45
PB Ratio
6.04
Book Value
317.84
EBITDA
2,153.00
Dividend Yield
0.31 %
Industry
Healthcare
Sector
Pharmaceuticals
Return on Equity
12.51
Debt to Equity
0.14
Analyst Rating and Forecast
- By Refinitiv from15 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+80.00 %
+80.00 %
Hold
Hold+13.33 %
+13.33 %
Sell
Sell+6.67 %
+6.67 %
Forecast For
Actual

Company News

View All News
Caret
positive
IPCA Labs raises FY27 EBITDA margin guide10 days ago
IPCA Laboratories raises its EBITDA margin guidance for FY27 to 23%. The pharma major plans to expand capacity and R&D facilities to meet demand in the US and European markets.
neutral
Ipca Labs AGM: Shareholders approve key resolutionsAug 14, 2026
Ipca Laboratories shareholders passed all resolutions at the 76th AGM, including director re-appointments and dividend declaration, with promoter support.
positive
IPCA Labs Q1: Profit surges 72% on margin expansionAug 13, 2026
IPCA Laboratories reported a 71.7% YoY rise in Q1 net profit to ₹4.0 billion, driven by revenue growth of 21.2% and EBITDA margin expansion from 18% to 24%.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,922.00
#1 4,61,152.18
37.82
#1 61,673.90
12.69
#1 11,565
26.53
45.69
Divis Laboratories
8,744.50
2,32,139.00
77.15
11,067.00
13.95
2,568
65.50
67.19
Torrent Pharmaceuticals
4,932.00
1,87,597.43
85.76
13,886.20
20.34
2,138
3.28
48.05
Cipla
1,422.00
1,14,875.60
34.55
29,044.60
2.24
3,870
-39.18
48.21
Zydus Life Science
1,124.50
1,13,151.01
23.91
27,657.90
17.64
5,026
-34.90
44.37
Laurus Labs
1,866.20
1,00,748.04
89.01
6,867.80
22.01
890
#1 123.93
59.80
Dr Reddys Laboratories
1,193.50
99,617.75
31.32
35,058.60
3.90
4,158
-69.10
48.40
Lupin
2,175.50
99,470.94
#1 18.04
29,038.90
#1 26.75
5,356
16.00
27.99
Mankind Pharma
2,365.00
97,673.55
47.44
14,636.40
14.85
1,938
29.13
38.57
Aurobindo Pharma
1,617.80
93,084.64
24.96
34,145.20
5.56
3,503
25.21
51.29
Growth Rate
Revenue Growth
8.73 %
Net Income Growth
51.29 %
Cash Flow Change
-13.57 %
ROE
33.23 %
ROCE
26.29 %
EBITDA Margin (Avg.)
8.84 %

Quarterly Financial Results

Quarterly Financials
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
890
1,027
1,020
895
1,099
1,299
1,231
1,088
1,547
1,377
1,425
1,135
1,587
1,563
1,443
1,304
1,608
1,637
1,577
1,548
1,630
2,073
2,144
2,052
2,113
2,381
2,266
2,273
2,342
2,584
2,430
2,482
2,813
Expenses
757
838
772
716
881
1,019
942
908
947
1,003
1,045
886
1,152
1,184
1,123
1,070
1,317
1,341
1,330
1,331
1,278
1,713
1,722
1,848
1,700
1,913
1,782
2,023
1,892
2,070
1,859
1,950
2,119
EBITDA
133
188
247
179
218
279
289
180
599
374
380
249
435
378
320
234
291
296
247
217
353
360
422
204
413
468
483
250
449
515
571
532
695
Operating Profit %
14 %
17 %
23 %
19 %
18 %
21 %
22 %
15 %
38 %
26 %
26 %
21 %
26 %
23 %
22 %
17 %
17 %
16 %
14 %
12 %
19 %
16 %
16 %
9 %
19 %
19 %
21 %
10 %
18 %
19 %
22 %
18 %
24 %
Depreciation
47
45
46
45
46
50
51
64
51
52
54
53
56
57
59
61
62
64
67
70
69
90
100
98
99
100
99
100
100
103
108
107
111
Interest
5
2
5
6
5
4
4
4
3
2
2
2
2
1
1
3
7
9
11
19
31
44
33
29
24
23
17
22
19
20
18
20
12
Profit Before Tax
82
141
197
128
167
225
234
112
546
319
324
195
377
320
260
170
223
223
169
129
252
225
289
77
290
345
368
128
331
392
446
405
572
Tax
13
22
37
32
37
32
37
29
100
53
57
33
71
68
62
38
78
77
60
51
88
89
68
75
91
99
92
64
98
111
82
98
148
Net Profit
69
119
159
96
129
194
198
83
446
267
268
161
307
252
198
132
145
146
110
78
164
137
221
1
199
246
276
64
233
281
364
307
424
EPS in ₹
5.43
9.38
12.59
7.60
10.24
15.32
15.63
6.57
35.27
21.11
21.09
12.71
24.18
19.73
7.76
5.13
5.64
5.67
4.25
3.02
6.42
5.72
7.09
2.35
7.58
9.05
9.78
2.67
9.19
11.14
12.86
13.31
15.84
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Total Assets
3,812
3,892
3,960
4,117
4,551
5,260
6,068
7,639
8,626
11,101
11,761
12,370
Fixed Assets
1,800
2,014
1,983
1,953
1,940
2,059
2,072
2,418
2,751
4,553
4,267
4,627
Current Assets
1,614
1,622
1,742
1,946
2,378
2,856
3,437
4,447
5,189
5,536
5,967
6,374
Capital Work in Progress
267
129
95
73
66
133
235
306
140
343
622
773
Investments
0
26
136
87
120
310
505
989
626
862
980
844
Other Assets
1,745
1,723
1,746
2,005
2,424
2,758
3,256
3,926
5,109
5,343
5,893
6,127
Total Equity & Liabilities
3,812
3,892
3,960
4,117
4,551
5,260
6,068
7,639
8,626
11,101
11,761
12,370
Current Liabilities
904
970
956
1,008
1,098
1,326
1,161
1,466
1,806
2,356
2,386
2,307
Non Current Liabilities
700
663
548
421
315
292
192
604
905
1,019
986
539
Total Equity
2,208
2,259
2,455
2,689
3,138
3,641
4,716
5,569
5,915
7,727
8,388
9,524
Reserve & Surplus
2,183
2,234
2,430
2,663
3,097
3,590
4,676
5,467
5,817
6,307
6,923
8,038
Share Capital
25
25
25
25
25
25
25
25
25
25
25
25
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Net Cash Flow
29
29
-26
75
153
-76
264
432
588
-823
169
142
Investing Activities
-689
-218
-149
-135
-165
-509
-521
-851
-725
-1,215
-870
-247
Operating Activities
468
709
282
341
501
570
1,090
856
806
945
1,321
1,142
Financing Activities
251
-462
-159
-130
-183
-137
-306
427
507
-553
-283
-754
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Jun 2026
Promoter
46.29 %
46.29 %
46.29 %
46.29 %
46.29 %
46.29 %
46.29 %
46.29 %
46.29 %
46.29 %
46.29 %
46.29 %
46.30 %
46.30 %
46.30 %
44.72 %
44.72 %
44.72 %
44.72 %
44.72 %
44.72 %
44.72 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.02 %
0.02 %
0.02 %
0.00 %
9.86 %
0.00 %
10.51 %
10.85 %
10.83 %
11.07 %
10.76 %
10.67 %
10.43 %
10.63 %
10.63 %
10.73 %
DIIs
24.49 %
24.86 %
25.00 %
29.73 %
32.41 %
33.31 %
33.29 %
34.03 %
33.55 %
35.19 %
35.05 %
33.79 %
34.37 %
33.78 %
34.23 %
35.68 %
36.06 %
36.20 %
36.77 %
37.32 %
37.45 %
37.37 %
Government
0.28 %
0.22 %
0.22 %
0.24 %
0.24 %
0.24 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
8.74 %
8.25 %
7.61 %
7.75 %
7.79 %
7.50 %
7.44 %
7.41 %
7.26 %
6.98 %
7.14 %
7.12 %
7.13 %
7.27 %
6.93 %
6.88 %
6.81 %
6.82 %
6.55 %
5.88 %
5.79 %
5.76 %
Others
20.20 %
20.39 %
20.89 %
15.99 %
13.27 %
12.66 %
12.97 %
12.26 %
12.89 %
11.54 %
1.67 %
12.80 %
1.69 %
1.79 %
1.71 %
1.65 %
1.65 %
1.59 %
1.53 %
1.44 %
1.41 %
1.42 %
No of Share Holders
1,00,626
1,05,428
95,239
1,06,779
1,15,335
1,10,818
1,11,043
1,08,177
1,10,296
99,889
95,930
82,809
81,165
84,753
82,975
90,189
88,306
85,582
82,870
77,673
82,184
82,060

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 1 1 3 5 8 8 4 4 4 0.00
Dividend Yield (%) 0.31 0.2 0.43 0.53 0.75 1.02 0.32 0.27 0.25 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
23 Nov 2021 DIVIDEND Dividend
₹ 8.00 /share
 22 Nov 2021 1,110.28 1,015.88
23 Nov 2022 DIVIDEND Dividend
₹ 4.00 /share
 22 Nov 2022 889.60 863.85
22 Nov 2023 DIVIDEND Dividend
₹ 2.00 /share
 22 Nov 2023 1,046.40 1,074.90
07 Aug 2024 DIVIDEND Dividend
₹ 2.00 /share
 06 Aug 2024 1,319.35 1,320.95
13 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 13 Aug 2024 1,218.00 1,381.60
14 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 14 Nov 2024 1,564.70 1,504.85
27 Nov 2024 DIVIDEND Dividend
₹ 2.00 /share
 27 Nov 2024 1,504.85 1,564.90
13 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 13 Feb 2025 1,515.65 1,420.40
29 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 29 May 2025 1,404.20 1,495.70
05 Aug 2025 DIVIDEND Dividend
₹ 2.00 /share
 05 Aug 2025 1,495.70 1,442.15
11 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 11 Aug 2025 1,444.40 1,384.55
11 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 11 Aug 2025 1,462.05 1,384.55
13 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 13 Nov 2025 1,287.90 1,340.90
13 Feb 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 13 Feb 2026 1,480.90 1,472.90
29 May 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 29 May 2026 1,530.90 1,572.40
07 Aug 2026 DIVIDEND Dividend
₹ 6.00 /share
 07 Aug 2026 1,572.40 1,733.45
13 Aug 2026 ANNUAL GENERAL MEETING Annual General Meeting
NA
 13 Aug 2026 1,787.90 1,766.70
13 Aug 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 13 Aug 2026 1,777.25 1,766.70

Announcements

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome8 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome10 days ago
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2026
Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 14, 2026
Shareholder Meeting / Postal Ballot-Outcome of AGMAug 13, 2026
Standalone And Consolidated Unaudited Financial Results For Q1FY27Aug 13, 2026
Board Meeting Outcome for Standalone And Consolidated Unaudited Financial Results For Q1FY27Aug 13, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 06, 2026
Board Meeting Intimation for Standalone And Consolidated Financial Results For 1St Quarter Ended 30Th June 2026Jul 28, 2026
Intimation Of Web Link To Non-Email CasesJul 17, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 15, 2026
Record Date For DividendJul 14, 2026
76Th Annual General Meeting Of Ipca Laboratories Limited To Be Held On Thursday 13Th August 2026Jul 14, 2026
Business Responsibility and Sustainability Reporting (BRSR)Jul 14, 2026
Reg. 34 (1) Annual Report.Jul 14, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 13, 2026
Announcement under Regulation 30 (LODR)-Credit RatingJul 07, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 02, 2026
Announcement under Regulation 30 (LODR)-Scheme of ArrangementJun 26, 2026
Board Meeting Outcome for Outcome Of Board MeetingJun 26, 2026
Closure of Trading WindowJun 22, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 12, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 09, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJun 04, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJun 01, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 01, 2026
Revised Link For Q4FY26 Conference Call To Be Held TodayJun 01, 2026
Announcement under Regulation 30 (LODR)-Dividend UpdatesMay 29, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementMay 29, 2026
Standalone And Consolidated Results Q4FY26May 29, 2026
Board Meeting Outcome for Outcome Of Board MeetingMay 29, 2026
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 27, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 21, 2026
Board Meeting Intimation for Standalone And Consolidated Financial Results For 4Th Quarter And Financial Year Ended 31St March 2026 And DividendMay 04, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 08, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 02, 2026
Closure of Trading WindowMar 16, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 18, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 16, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 16, 2026
Standalone And Consolidated Financial Results For Q3FY26Feb 13, 2026
Board Meeting Outcome for Standalone And Consolidated Financial Results For Q3FY26Feb 13, 2026
Commencement Of Commercial Production At Companys New Manufacturing Unit Situated At Village Hingani District - WardhaFeb 09, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 06, 2026
Board Meeting Intimation for Standalone And Consolidated Unaudited Financial Results For The 3Rd Quarter And Nine Months Ended 31St December 2025Jan 22, 2026
Board Meeting Intimation for Standalone And Consolidated Unaudited Financial Results For The 3Rd Quarter And Nine Months Ended 31St December 2025Jan 22, 2026
Re-Lodgement Of Transfer Request Report - November 2025 And December 2025Jan 21, 2026
Sale Of 100% Equity Shares Of Wholly Owned Step-Down Subsidiary And Updation Of Registered Office AddressJan 13, 2026
Announcement under Regulation 30 (LODR)-Change in Registered Office AddressJan 13, 2026
Board Meeting Outcome for Outcome Of Board MeetingJan 13, 2026

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
JioBlackRock Flexi Cap Fund Direct-Growth
0.00%
-20628
-0.11%
0.00%
TRUSTMF Mid Cap Fund Direct-Growth
0.00%
-20216
-1.10%
-0.67%
The Wealth Company Flexi Cap Fund Direct-Growth
0.71%
-20141
-1.43%
-0.87%
Baroda BNP Paribas Health and Wellness Fund Direct-Growth
5.72%
-18750
-0.08%
0.54%
Sundaram Multi-Factor Fund Direct-Growth
0.88%
-1459
0.01%
0.88%
JioBlackRock Large Cap Fund Direct-Growth
0.00%
-885
-0.36%
-0.35%
Tata Nifty Midcap 150 Index Fund Direct-Growth
0.58%
494
0.00%
0.05%
JioBlackRock Nifty Midcap 150 Index Fund Direct-Growth
0.58%
294
0.00%
0.05%
Zerodha Life Cycle Fund 2041 Direct-Growth
0.23%
188
0.23%
0.23%
Zerodha Life Cycle Fund 2036 Direct-Growth
0.19%
166
0.19%
0.19%
Zerodha Nifty LargeMidcap250 Plus 8-13 Yr G-Sec 70:30 Index Fund Direct-Growth
0.21%
-83
0.00%
0.07%
DSP Nifty Healthcare Index Fund Direct-Growth
2.11%
78
-0.06%
0.08%
JioBlackRock Sector Rotation Fund Direct-Growth
0.19%
-78
-0.01%
0.03%
Kotak Nifty Midcap 150 Index Fund Direct-Growth
0.58%
66
0.00%
0.05%
Edelweiss Nifty LargeMidcap250 Plus 8-13 Yr G-Sec 70:30 Index Fund Direct-Growth
0.20%
41
0.00%
0.01%
Zerodha Nifty MidSmallcap400 50:50 Index Fund Direct-Growth
0.29%
39
0.01%
0.03%
UTI Nifty500 Shariah Index Fund Direct-Growth
0.41%
-19
-0.01%
0.04%
Groww Nifty Midcap 150 Index Fund Direct-Growth
0.58%
-19
0.00%
0.05%
DSP Nifty Midcap 150 Index Fund Direct-Growth
0.58%
18
0.00%
0.06%
Motilal Oswal BSE 1000 Index Fund Direct-Growth
0.12%
-8
0.01%
0.01%
Navi Nifty MidSmallcap 400 Index Fund Direct-Growth
0.38%
-3
0.00%
0.03%
DSP Nifty 500 Index Fund Direct-Growth
0.12%
1
0.00%
0.01%
ICICI Prudential Nifty Midcap 150 Index Fund Direct-Growth
0.58%
0
0.00%
0.00%
Kotak Aggressive Hybrid Fund Direct-Growth
1.25%
0
0.00%
0.00%
Bank of India Midcap Tax Fund Series 1 Direct-Growth
0.00%
0
0.00%
0.00%

Technical Indicators

RSI(14)
Neutral
65.27
ATR(14)
Less Volatile
66.79
STOCH(9,6)
Overbought
83.09
STOCH RSI(14)
Overbought
99.30
MACD(12,26)
Bullish
16.33
ADX(14)
Strong Trend
25.61
UO(9)
Bearish
51.25
ROC(12)
Uptrend And Accelerating
10.74
WillR(14)
Overbought
-9.12
Bearish
5
Neutral
1
Bullish
3

About IPCA Laboratories

Ipca Laboratories Limited is an Indian integrated pharmaceutical company that manufactures and markets over 350 formulations and 80 active pharmaceutical ingredients (APIs) across various therapeutic segments. The company operates 18 manufacturing units in India and sells its products in over 100 countries worldwide. Ipca specializes in producing APIs such as...more
Website
https://www.ipca.com
Chairperson NamePremchand Godha
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Fundamental Screeners
Technical Screeners
Intraday Screeners
Price & Volume Screeners
Candlestick Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.
We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.
This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.
The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.
We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.
This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.
By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.
We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.

© 2025 - 2026 Raise Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016 | SEBI Research Analyst Registration No: INH000023357 Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104